On the effects of partial agonists of dopamine receptors for the treatment of schizophrenia

Pharmacopsychiatry

Volumn 40, Issue SUPPL. 1, 2007, Pages

  Koch, M ^a  

^a UNIVERSITY OF BREMEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APLINDORE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BIFEPRUNOX; CHLORPROMAZINE; CLOZAPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; HISTAMINE; MUSCARINIC RECEPTOR; NEUROTRANSMITTER; NORADRENALIN; OLANZAPINE; PLACEBO; SEROTONIN 1A RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG;

ADDICTION; BINDING AFFINITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; DIABETES MELLITUS; DOPAMINE RELEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PSYCHOSIS; QT PROLONGATION; RELAPSE; SCHIZOPHRENIA; SEROTONIN RELEASE; SIDE EFFECT; SYMPTOMATOLOGY; WEIGHT GAIN; WORKING MEMORY;

EID: 37549029157     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-990303     Document Type: Conference Paper

References (52)

1. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, Dyck CH van, Charney DS, Innis RB, Lamelle M. increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 1998; 155: 761-767
2. 1 receptors and working memory in schizophrenia. J Neurosci 2002; 22: 3708-3719
3. 2 dopamine receptor colocalization in neostriatal neurons. Nat Neurosci 2000; 3: 226-230
4. Andrezina R, Josiassen RC, Marcus RN, Oren DA, Manos G, Stock E, Carlson WH, Iwamoto T. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology 2006; 188: 281-292
5. Bortolozzi A, Diaz-Mataix L, Toth M, Celada P, Artigas F. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology 2007; 191: 745-758
6. Callicott JH, Mattay VS, Verchinski BA, Egan MF, Weinberger DR. Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down. Am J Psychiatry 2003; 160: 2209-2215
7. Carlsson A. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry 2006; 39: S10-S14
8. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 2001; 41: 237-260
9. Carlsson ML, Carlsson A, Nilsson M. Schizophrenia: from dopamine to glutamate and back. Curr Med Chem 2004; 11: 267-277
10. Cragg SJ, Rice ME. DAncing past the DAT at a DA synapse. Trends Neurosci 2004; 27: 270-277
11. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192: 481-483
12. Cutler AJ, Marcus RN, Hardy SA, O'Donnell A, Carson WH, MacQuade RD. The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS Spectr 2006; 11: 691-702
13. Davies M, Sheffler D, Roth B. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev 2004; 10: 317-336
14. Durstewitz D. A few important points about dopamine's role in neural network dynamics. Pharmacopsychiatry 2006; 39: S72-S75
15. Durstewitz D, Seamans JK, Sejnowski TJ. Neurocomputational models of working memory. Nat Neurosci 2000; 3: 1184-1191
16. Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49: 538-544
17. Frankle WG, Lerma J, Lamelle M. The synaptic hypothesis of schizophrenia. Neuron 2003; 39: 205-216
18. Goldman-Rakic PS, Castner SA. Svensson TH, Siever LJ, Williams GV. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology 2004; 174: 3-16
19. Grace AA. Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Res Rev 2000; 31: 330-341
20. Gründer G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications. Arch Gen Psychiatry 2003; 60: 974-977
21. Gründer G, Kungel M, Ebrecht M, Göröcs T, Modell S. Aripiprazole: Pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry 2006; 39: S21-S25
22. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2006; 64: 2291-2314
23. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005; 10: 40-68
24. Heinrich JN, Brennan J, Lai MH, Sullivan K, Hornby G, Popiolek M, Jiang LX, Pausch MH, Stack G, Marquis KL, Andree TH. Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist. Eur J Pharmacol 2006; 552: 36-45
25. 1A receptor agonism. Brain Res 2002; 956: 349-357
26. Kane JM, Carson WH, Saha AH, MacQuade RD, Ingenito GG, Zimbroff DL, Ali MW. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63: 763-771
27. Kenakin T. Principles: Receptor theory in pharmacology. Trends Pharmacol Sci 2004; 25: 186-192
28. Kern RS, Green MF, Cornblatt BA, Owen JR, MacQuade RD, Carson WH, Ali M, Marcus R. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology 2006; 187: 312-320
29. Koch M. Animal models of schizophrenia. in: Koch M (ed): Animal Models of Neuropsychiatric Diseases. London, Imperial College Press, pp 337-402
30. Lavin A, Nogueira RL, Lapish CC, Wightman RM, Phillipps PE, Seamans JK. Mesocortical dopamine neurons operate in distinct temporal domains using multimodal signaling. J Neurosci 2005; 25: 5013-5023
31. Leuner K, Müller WE. The complexity of the dopaminergic synapses and their modulation by antipsychotics. Pharmacopsychiatry 2006; 39: S15-S20
32. Li Z, Ichikawa J, Dai J, Meltzer HY. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 2004; 493: 75-83
33. Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 2004; 18: 251-267
34. Marder SR, MacQuade RD, Stock EG, Kaplita SB, Marcus R, Safferman AZ, Saha A, Ali MW, Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerabilityin short-term, placebo-controlled trials. Schizophr Res 2003; 61: 123-136
35. Meller E, Bohmaker K, Namba Y, Friedhoff AJ, Goldstein M. Relationship between receptor occupancy and responses at striatal dopamine autoreceptors. Mol Pharmacol 1987; 31: 592-598
36. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005; 10: 79-104
37. Murphy BP, Chung YC, Park TW, MacGorry PD. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 2006; 88: 5-25
38. Nicola SM, Surmeier DJ, Malenka RC. Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. Annu Rev Neurosci 2000; 23: 185-215
39. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997; 385: 634-636
40. Pigott TA, Carlson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003; 64: 1048-1056
41. 3 receptor agonist. Nature 1999; 400: 371-375
42. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681-690
43. Pulvirenti L, Koob GF. Being partial to psychostimulant addiction therapy. Trends Pharmacol Sci 2002; 23: 151-153
44. Schwabe K, Koch M. Effects of aripiprazole on operant responding for a natural reward after psychostimulant withdrawal in rats. Psychopharmacology 2007; 191: 759-765
45. Sesack SR, Carr DB. Selective prefrontal cortex inputs to dopamine cells: implications for schizophrenia. Physiol Behav 2002; 77: 513-517
46. Takahashi H, Higuchi M, Suhara T. The role of extrastriatal dopaine D2 receptors in schizophrenia. Biol Psychiatry 2006; 59: 919-928
47. Tamminga CA. Partial dopamine agonists in the treatment of psychosis. J Neural Transm 2002; 109: 411-420
48. Tamminga CA, Schaffer MH, Smith RC, Davis JM. Schizophrenic symptoms improve with apomorphine. Science 1978; 200: 567-568
49. Taylor DM. Aripiprazole: a review of its pharmacology and clinical use. Int J Clin Pract 2003; 57: 49-54
50. Winterer G. Cortical microcircuits in schizophrenia - the dopamine hypothesis revisited. Pharmacopsychiatry 2006; 39: S68-S71
51. 3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597) a study using positron emission tomography and [11C] raclopride. Neuropsychopharmacology 2002; 27: 248-259
52. Zocchi A, Fabbri D, Heidbreder CA. Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neurosci Lett 2005; 387: 157-161